<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685477</url>
  </required_header>
  <id_info>
    <org_study_id>CCK-2008</org_study_id>
    <nct_id>NCT00685477</nct_id>
  </id_info>
  <brief_title>Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying</brief_title>
  <official_title>Dose Response of Intravenous Sincalide (CCK-8) for Gallbladder Emptying</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Health University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study to establish normal values for the infusion of a synthetic
      form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is
      released from the small bowel to stimulate the pancreas and gallbladder to help digest and
      absorb food. Some people have gallbladder problems and need to be tested with the synthetic
      cholecystokinin ( KinevacÂ®, Bracco Diagnostics, Inc.). The aim of this study is to find out
      how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying.
      The findings in normal subjects will be used to establish normal values that can then be
      compared with patients with suspected gallbladder disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study enrolled 60 healthy volunteers from four institutions (Johns Hopkins University,
      Pennsylvania State University, Memorial Health University Medical Center, and Temple
      University. Subjects had to be healthy men or women 18-65 years old with no gastrointestinal
      disease as confirmed by initial screening using a modified Mayo Clinic Research
      Gastrointestinal Disease Screening Questionnaire, and normal results for CBC, metabolic
      profile, serum amylase and gallbladder ultrasonography. Women could not be enrolled if
      pregnant.

      Subjects had 3 infusion studies at least 2 days apart within 3 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of Variation (CV) for Gallbladder Ejection Fraction (GBEF) for Each Infusion Method</measure>
    <time_frame>15, 30, 45, and 60 minutes post drug infusion</time_frame>
    <description>The primary statistical endpoint was the CV as a measure of variability for the GBEF for each infusion method at the different intervals to determine which sincalide infusion method had the lowest variation. The CV is the SD divided by the mean and is expressed as a percentage and reflects the variability among the values. The infusion method having the lowest CV is considered best as it reflects the lowest variability of the values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gallbladder Ejection Fraction (GBEF) as a Percent for Each Infusion Method</measure>
    <time_frame>15, 30, 45 and 60 minutes post-infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Experimental Sequence ABC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Sequence ACB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Sequence BAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Sequence BCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Sequence CAB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Sequence CBA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Sequence ABC</intervention_name>
    <description>Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes</description>
    <arm_group_label>Experimental Sequence ABC</arm_group_label>
    <other_name>Sequence ABC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Sequence ACB</intervention_name>
    <description>Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes</description>
    <arm_group_label>Experimental Sequence ACB</arm_group_label>
    <other_name>Sequence ACB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Sequence BAC</intervention_name>
    <description>Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion</description>
    <arm_group_label>Experimental Sequence BAC</arm_group_label>
    <other_name>Sequence BAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Sequence BCA</intervention_name>
    <description>Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion</description>
    <arm_group_label>Experimental Sequence BCA</arm_group_label>
    <other_name>Sequence BCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Sequence CAB</intervention_name>
    <description>Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion</description>
    <arm_group_label>Experimental Sequence CAB</arm_group_label>
    <other_name>Sequence CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Sequence CBA</intervention_name>
    <description>Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion</description>
    <arm_group_label>Experimental Sequence CBA</arm_group_label>
    <other_name>Sequence CBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females between ages 18-65 years of age with no gastrointestinal
             disease as screened by the Mayo Clinic GI Disease Screening Questionnaire

          2. Subjects with high probability for compliance and completion of the study

          3. Normal liver function tests and amylase

          4. Normal ultrasound of the gallbladder

        Exclusion Criteria:

          1. Prior GI surgery, excluding appendectomy

          2. Surgery within the past 3 months

          3. BMI &gt; 35

          4. Female of childbearing age who is not practicing birth control and/or is pregnant or
             lactating. (Confirm with urine pregnancy test)

          5. Cardiovascular, endocrine, renal, gastrointestinal, or other chronic disease likely to
             affect motility. This includes diabetes, renal insufficiency, gastroesophageal reflux
             disease, gastroparesis, irritable bowel syndrome, prior peptic ulcer disease.

          6. GI symptoms such as heartburn, chest pain, dysphagia, abdominal pain, nausea,
             vomiting, constipation, diarrhea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan H Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J. Functional gallbladder and sphincter of oddi disorders. Gastroenterology. 2006 Apr;130(5):1498-509. Review.</citation>
    <PMID>16678563</PMID>
  </reference>
  <results_reference>
    <citation>Ziessman HA, Tulchinsky M, Lavely WC, Gaughan JP, Allen TW, Maru A, Parkman HP, Maurer AH. Sincalide-stimulated cholescintigraphy: a multicenter investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. J Nucl Med. 2010 Feb;51(2):277-81. doi: 10.2967/jnumed.109.069393. Epub 2010 Jan 15.</citation>
    <PMID>20080900</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <results_first_submitted>December 28, 2016</results_first_submitted>
  <results_first_submitted_qc>December 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2017</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Temple University</investigator_affiliation>
    <investigator_full_name>Alan Maurer</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>CCK infusion</keyword>
  <keyword>Gallbladder ejection fraction</keyword>
  <keyword>Normal volunteers</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Sequence ABC</title>
          <description>Drug given over 15 minutes infusion followed by infusion over 30 minutes, followed by infusion over 60 minutes</description>
        </group>
        <group group_id="P2">
          <title>Experimental Sequence ACB</title>
          <description>Drug given over 15 minutes infusion followed by infusion over 60 minutes, followed by infusion over 30 minutes</description>
        </group>
        <group group_id="P3">
          <title>Experimental Sequence BAC</title>
          <description>Drug given over 30 minutes infusion followed by infusion over 15 minutes, followed by infusion over 60 minutes</description>
        </group>
        <group group_id="P4">
          <title>Experimental Sequence BCA</title>
          <description>Drug given over 30 minutes infusion followed by infusion over 60 minutes, followed by infusion over 15 minutes</description>
        </group>
        <group group_id="P5">
          <title>Experimental Sequence CAB</title>
          <description>Drug given over 60 minutes infusion followed by infusion over 15 minutes, followed by infusion over 30 minutes</description>
        </group>
        <group group_id="P6">
          <title>Experimental Sequence CBA</title>
          <description>Drug given over 60 minutes infusion followed by infusion over 30 minutes, followed by infusion over 15 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Each of the 60 subjects had 3 infusion studies at least 2 days apart.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>CCK-8 0.02 mg/kg over 15, 30 or 60 minutes: Drug will be given over infusions at different time periods. All participants received all treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coefficient of Variation (CV) for Gallbladder Ejection Fraction (GBEF) for Each Infusion Method</title>
        <description>The primary statistical endpoint was the CV as a measure of variability for the GBEF for each infusion method at the different intervals to determine which sincalide infusion method had the lowest variation. The CV is the SD divided by the mean and is expressed as a percentage and reflects the variability among the values. The infusion method having the lowest CV is considered best as it reflects the lowest variability of the values.</description>
        <time_frame>15, 30, 45, and 60 minutes post drug infusion</time_frame>
        <population>Some participants were excluded from analyses due to location testing procedures</population>
        <group_list>
          <group group_id="O1">
            <title>15min Infusion</title>
            <description>Drug given over 15 minutes infusion</description>
          </group>
          <group group_id="O2">
            <title>30 Min Infusion</title>
            <description>Drug given over 30 minutes infusion</description>
          </group>
          <group group_id="O3">
            <title>60 Min Infusion</title>
            <description>Drug given over 60 minutes infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Coefficient of Variation (CV) for Gallbladder Ejection Fraction (GBEF) for Each Infusion Method</title>
          <description>The primary statistical endpoint was the CV as a measure of variability for the GBEF for each infusion method at the different intervals to determine which sincalide infusion method had the lowest variation. The CV is the SD divided by the mean and is expressed as a percentage and reflects the variability among the values. The infusion method having the lowest CV is considered best as it reflects the lowest variability of the values.</description>
          <population>Some participants were excluded from analyses due to location testing procedures</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 min post infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.66" lower_limit="43.79" upper_limit="63.01"/>
                    <measurement group_id="O2" value="62.75" lower_limit="53.19" upper_limit="76.53"/>
                    <measurement group_id="O3" value="71.38" lower_limit="60.52" upper_limit="87.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.46" lower_limit="33.49" upper_limit="51.10"/>
                    <measurement group_id="O2" value="34.49" lower_limit="29.23" upper_limit="42.06"/>
                    <measurement group_id="O3" value="35.81" lower_limit="30.36" upper_limit="43.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 min post infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.91" lower_limit="33.05" upper_limit="50.42"/>
                    <measurement group_id="O2" value="31.30" lower_limit="25.91" upper_limit="39.53"/>
                    <measurement group_id="O3" value="24.00" lower_limit="20.35" upper_limit="29.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min post infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.21" lower_limit="29.15" upper_limit="44.48"/>
                    <measurement group_id="O2" value="29.11" lower_limit="24.10" upper_limit="36.77"/>
                    <measurement group_id="O3" value="18.55" lower_limit="15.73" upper_limit="22.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gallbladder Ejection Fraction (GBEF) as a Percent for Each Infusion Method</title>
        <time_frame>15, 30, 45 and 60 minutes post-infusion</time_frame>
        <population>Some participants were excluded from analyses due to location testing procedures</population>
        <group_list>
          <group group_id="O1">
            <title>15 Minute Infusion</title>
            <description>Drug given over 15 minutes</description>
          </group>
          <group group_id="O2">
            <title>30 Minute Infusion</title>
            <description>Drug given over 30 minutes</description>
          </group>
          <group group_id="O3">
            <title>60 Minute Infusion</title>
            <description>Drug given over 60 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Gallbladder Ejection Fraction (GBEF) as a Percent for Each Infusion Method</title>
          <population>Some participants were excluded from analyses due to location testing procedures</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes post-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="29"/>
                    <measurement group_id="O2" value="44" spread="28"/>
                    <measurement group_id="O3" value="34" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" spread="27"/>
                    <measurement group_id="O2" value="71" spread="24"/>
                    <measurement group_id="O3" value="64" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes post-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" spread="26"/>
                    <measurement group_id="O2" value="73" spread="23"/>
                    <measurement group_id="O3" value="78" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" spread="24"/>
                    <measurement group_id="O2" value="74" spread="21"/>
                    <measurement group_id="O3" value="84" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 min, 30 min, 45 min, and 60 min post-infusion</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>Drug given over 15 minute infusion to look at lowest coefficient of variation in infusion, followed by infusion over 30 minutes, followed by infusion over 60 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Maurer, MD</name_or_title>
      <organization>Temple University</organization>
      <phone>215-707-8269</phone>
      <email>amaurer@temple.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

